Multiple Sclerosis Therapeutic Market Analysis

  • Report ID: 6549
  • Published Date: Oct 11, 2024
  • Report Format: PDF, PPT

Multiple Sclerosis Therapeutic Market Analysis

 Route of Administration (Oral, Injectables)

In route of administration, oral segment is set to hold multiple sclerosis therapeutic market share of more than 58.5% by 2037. It is easier to monitor oral medications than injectable therapies, making a patient more compliant and convenient. The patients are allowed to take medication at home, in the absence of any medical supervision, thus enhancing their treatment process.
This convenience leads to adherence to the treatment routine, which is critical in chronic conditions including multiple sclerosis, as it demands a thorough treatment to manage symptoms, thereby, slowing disease progression. Moreover, continuous innovation in oral formulations, with improved safety profiles and efficacy in treating both relapsing and progressive MS, has further solidified their dominance in the market. For instance, in March 2019, the U.S. FDA approved Novartis’ Mayzent tablets to treat adults with relapsing forms of multiple sclerosis.

Distribution Channel (Hospital pharmacy, Retail pharmacy, Online Pharmacy)

In distribution channel, the hospital segment in multiple sclerosis therapeutic market is projected to witness a considerable growth during the forecast period, owing to their central role in diagnosing, managing, and treating the disease. Hospitals serve as key points for the administration of high-cost and complex therapies, including biologics, and monoclonal antibodies. These often need specialist supervision, and intravenous delivery in some cases. In addition, hospitals have necessary infrastructure for administering treatments that require refrigeration and specialized handling, making them a preferred channel for distributing these advanced therapies. Furthermore, hospitals tend to offer comprehensive care, including physical therapy, counseling, and access to multidisciplinary teams, positioning them as dominant players in the multiple sclerosis therapeutic market.

Our in-depth analysis of the global market includes the following segments:

Drug Class

  • Immunosuppressants
  • Immunostimulants
  • Immunomodulators
  • Corticosteroids
  • Other drug classes

Route of Administration

  • Oral
  • Injectables
    • Intramuscular
    • Subcutaneous
    • Intravenous

Distribution Channel

  • Hospital pharmacy
  • Retail pharmacy
  • Online pharmacy 
Get more information on this report: Request Free Sample PDF

Browse Key Market Insights with Data Illustration:


Author Credits:  Radhika Pawar


  • Report ID: 6549
  • Published Date: Oct 11, 2024
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

In the year 2024, the industry size of the multiple sclerosis therapeutic market was over USD 26.4 billion.

The market size for the multiple sclerosis therapeutic market is projected to reach USD 46.8 billion by the end of 2037 expanding at a CAGR of 4.9% during the forecast period i.e., between 2025-2037.

The major players in the market are Bayer AG, Bristol-Myers Squibb Company, F. Hoffman-La Roche Ltd., Johnson & Johnson, and others.

In terms of route of administration segment, the oral segment is anticipated to garner the largest market share by 2037 and display lucrative growth opportunities during 2025-2037.

The market in North America is projected to hold the largest market share of 45.7% by the end of 2037 and provide more business opportunities in the future.
Inquiry Before Buying Request Free Sample
logo
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying
Inquiry Before Buying Request Free Sample